APS Booth Presentation: A Novel Approach to Drug Screening with Blood
Interpretation of urine opioid test results depends on the proportional relationship of parent drugs and drug metabolites. Such patterns are generally used to verify that a patient has been compliant with prescribed therapy, but may also be used to identify when patients have added a drug directly to urine to mimic compliance. This presentation will discuss typical and atypical patterns of buprenorphine and associated metabolite concentrations in urine, relative to the most likely interpretations regarding compliance with therapy.
Originally presented May 18, 2012 in Honolulu, Hawaii.
Gwendolyn A. McMillin, PhD
Medical Director, Toxicology and Trace Elements Laboratories, ARUP Laboratories
Co-Medical Director, Pharmacogenetics, ARUP Laboratories
Associate Professor of Pathology, University of Utah School of Medicine
Dr. McMillin is a medical director of the Toxicology and Trace Elements laboratories and co-medical director of Pharmacogenetics at ARUP, as well as an associate professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.